Publications by authors named "H Rathke"
Feasibility, Tolerability, and Preliminary Clinical Response of Fractionated Radiopharmaceutical Therapy with Bi-FAPI-46: Pilot Experience in Patients with End-Stage, Progressive Metastatic Tumors.
J Nucl Med
December 2024
Article Synopsis
- Radiopharmaceutical therapies (RPTs) using fibroblast activation protein (FAP) and FAP inhibitors (FAPIs) offer a new treatment option for patients with progressive metastatic cancers who have undergone multiple previous treatments.
- A study involving 6 patients with various types of metastatic solid tumors showed that fractionated Bi-FAPI-46 RPT was feasible and well tolerated, with no reported adverse effects.
- Initial results indicated mixed responses: one patient had a partial response, one had stable disease, while four experienced progressive disease, suggesting that while Bi-FAPI-46 RPT is promising, further research is needed to evaluate its effectiveness.
The aim of this work is to evaluate our clinical real-world data obtained with Ac-PSMA-617 (AcPSMA), which were acquired under compassionate care regulations in patients with advanced-stage prostate cancer. The objective parameters that could be derived from this evaluation are compared with previous literature about AcPSMA and Lu-PSMA-617 (LuPSMA). The medical files of all patients who had received AcPSMA on an individual patient basis at the Heidelberg University Hospital since January 2014 were analyzed retrospectively.
View Article and Find Full Text PDFPurpose: Evaluation of Y liver radioembolization post-treatment clinical data using a whole-body Biograph Vision Quadra PET/CT to investigate the potential of protocol optimization in terms of scan time and dosimetry.
Methods: 17 patients with hepatocellular carcinoma with median (IQR) injected activity 2393 (1348-3298) MBq were included. Pre-treatment dosimetry plan was based on Tc-MAA SPECT/CT with Simplicit90Y™ and post-treatment validation with Quadra using Simplicit90Y™ and HERMIA independently.
Purpose: The physical properties of yttrium-90 (Y) allow for imaging with positron emission tomography/computed tomography (PET/CT). The increased sensitivity of long axial field-of-view (LAFOV) PET/CT scanners possibly allows to overcome the small branching ratio for positron production from Y decays and to improve for the post-treatment dosimetry of Y of selective internal radiation therapy.
Methods: For the challenging case of an image quality body phantom, we compare a full Monte Carlo (MC) dose calculation with the results from the two commercial software packages Simplicit90Y and Hermes.
Background: Actinium-225 (Ac) prostate-specific membrane antigen (PSMA) radioligand therapy (RLT) is a novel therapy for metastatic castration-resistant prostate cancer (mCRPC). We aimed to report the safety and antitumour activity of Ac-PSMA RLT of mCRPC in a large cohort of patients treated at multiple centres across the world.
Methods: This retrospective study included patients treated at seven centres in Australia, India, Germany, and South Africa.